Publications by authors named "M A Arici"
Article Synopsis
- Neoadjuvant chemotherapy (NAC) enhances survival rates in breast cancer patients by improving the rate of pathologic complete response (pCR), but research on blood-based indexes to predict pCR has produced mixed results.
- A study of 304 patients used various blood indexes, including neutrophil-to-lymphocyte ratios (NLR), pan-immune inflammation values (PIV), and lactate dehydrogenase-albumin ratios (LAR), to assess their relationship with pCR and overall survival.
- Results showed that PIV was the most significant predictor of pCR, while a high LAR was associated with increased recurrence risk and poor disease-free survival, revealing crucial insights for breast cancer treatment strategies.
BACKGROUND Sarcopenia, characterized by loss of skeletal muscle mass and function, is linked to poor outcomes in cancer patients. In breast cancer, sarcopenia has been associated with reduced treatment tolerance and survival. However, its impact on patients with locally advanced breast cancer receiving neoadjuvant chemotherapy is understudied.
View Article and Find Full Text PDFPurpose: This study investigates the superiority of sterile lyophilized amniotic membrane extract (AME) prepared at a clinically correlated dose over amniotic membrane transplantation (AMT) in an experimental corneal wound model.
Methods: AME was prepared from a pool of five amniotic membranes. After homogenizing the membranes, they were lyophilized and sterilized by gamma radiation to obtain sterile, lyophilized AME powder.
Purpose: The purpose of this study is to surveil the injuries in wrestling according to the different age categories and wrestling styles throughout the competition season.
Methods: The study was designed as a descriptive study. The study was conducted during the wrestling competition season in 2023 (from January 2023 to July 2023), which includes 5 different age categories: U-15, U-17, U-20, U-23, and seniors, along with the Turkey National Wrestling Championships.
Article Synopsis
- The FLOW trial investigated the effects of semaglutide on cardiovascular (CV) events and death in individuals with type 2 diabetes and chronic kidney disease (CKD).
- Results showed that semaglutide lowered the risk of CV death, non-fatal heart attacks, and strokes by 18%, and overall mortality by 20% across various levels of CKD severity.
- The beneficial effects of semaglutide were consistent regardless of kidney function, protein levels in urine, or risk classification.